This guideline covers assessing and managing motor neurone disease ... our guidance are made by NICE’s prioritisation board. For more information on the principles and process see NICE-wide topic ...

Further information Decision makers have concluded that the clear rationale to not evaluate this product is due to it being a change to the formulation of an existing product as per section 7.1.3 of ...